

# Up-to-the-minute insights via Amplity Health's Real Time Market Intelligence (RTMi)

THERAPEUTIC AREA: Prostate Cancer


LIFECYCLE: Early stage

## CHALLENGE

- Client needed to understand the perceived unmet need for diagnostic testing in early-stage prostate cancer
- Client was looking to gain insight on the levels of evidence required by payers to obtain biomarker coverage in prostate cancer
- Client was hoping to discuss alternative approaches in development of genomic biomarkers and associated evidence
- Client wanted to test the value hypothesis of a new diagnostic test in early-stage prostate cancer

## STRATEGY

- Leverage Amplity Health's Medical Communications team's unique access to advisors pertinent to this initiative
- Provide strategic guidance to facilitate contracting, question design, ongoing participant management, weekly summaries, recommendations, executive summary, and strategic recommendations



\* Using established FMV rates per client guidelines. Advisors are paid milestone honoraria every 4 weeks based on work completed.

# Up-to-the-minute insights via Amplity Health's Real Time Market Intelligence (RTMi)

Therapeutic Area: Prostate Cancer

Lifecycle: Early stage



## SAMPLING OF PARTICIPANTS

Title	Plan Affiliation
<ul style="list-style-type: none"> <li>Medical Director</li> <li>Formulary and Contract Manager</li> <li>Medical Director</li> <li>Senior Medical Director</li> <li>Medical Director, Western Region</li> <li>Medical Director</li> <li>Medical Director</li> <li>Medical Director, NW Region</li> <li>Medical Director</li> <li>Chief Medical Officer</li> </ul>	<ul style="list-style-type: none"> <li>Rees-Sealy Medical Group/Sharp Healthcare</li> <li>SelectHealth</li> <li>HealthNet of California</li> <li>Priority Health</li> <li>WellPoint/Anthem</li> <li>Humana</li> <li>Aetna</li> <li>United Health Group</li> <li>Independence Blue Cross</li> <li>Harvard Pilgrim Health Care</li> </ul>



## SAMPLE OF INSIGHTS

- Overall, payers are not pleased with the value they are receiving for their spend in this category. Specific reasons for suboptimal value were provided.
- Plans are reluctant to manage initiation of ADT after PSA rise, citing lack of unequivocal evidence and lack of clinical pathways in prostate cancer
- Several plans (Harvard Pilgrim, United, Anthem) are moving toward narrow physician networks as a way to reduce variation in care
  - Performance-based contracts are becoming increasingly common
  - In national plans, the use of narrow networks varies by region
- None of the participating plans surveyed had different criteria for community vs academic-based urologists. Likewise, none had different criteria for urologists and medical oncologists
- Overall, advisors perceived that a diagnostic test that helped to stratify risk in prostate cancer could offer a great deal of value
- For payers, a risk stratification test would provide value by reducing variation in care
- For specific examples of the insights provided, send us an email at [contact@amplity.com](mailto:contact@amplity.com)